Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision to make Global Bioprocessing Simpler and more Efficient. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, as well as other industries involving bioprocessing (e.g. Synthetic Biology, IVD, CGT, etc.) . Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States.
GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.
As of the end of 2022, GBB has completed three financing rounds, raising over US $30 million.
Great Bay Bio, Chairman & Co-founder
Great Bay Bio, Chairman & Co-founder
Mr. Leung has over 15 years’ experience in the life science and finance industries. Currently, he is the Chairman of Great Bay Bio and also serves as Director in both Uni-bio Science Group and DotBio. He has broad experience in sourcing, evaluating and executing new growth opportunities, supporting the execution and alliance management of 8 deals, including the in-licensing of next generation oncology, inflammation and respiratory drugs from MNCs.
Mr. Leung also has extensive experience in the finance industry where he worked in healthcare investment banking in Merrill Lynch and a family office, helping evaluated IPO opportunities for multiple companies across the US and PRC. Up to date, Mr. Leung has led and successfully raised over USD 60M across multiple of his ventures. Mr. Leung was awarded the prestigious honour of World Outstanding Young Leaders Award from Yazhou Zhoukan in 2016, Entrepreneur of the Year from CAPITAL in 2017, Young Industrialist Awards of Hong Kong in 2020, and Gen.T Social Impact and Leader of Tomorrow 2021.
Mr. Leung is currently a Chartered Financial Analyst and a member of The Hong Kong Society of Financial Analysts. He was also elected the Vice Chairman of Pharmaceutical & Chemical group of the Federation of Hong Kong Industries (FHKI). Mr. Leung holds a BSc in Biochemistry from Imperial College London, an MSc in Pharmacology from the University of Oxford, and EMBA from Tsinghua-INSEAD. In addition, he holds a Professional Diploma in Corporate Governance & Directorship from the HongKong Institute of Directors.
Great Bay Bio, CEO & Co-founder
Great Bay Bio, CEO & Co-founder
Dr. Michael Chen has more than 30 years of experience in technology, operation management, and partnership in biopharmaceutical companies at home and abroad. Dr. Chen has served as process development director, production director, partner, etc. in 6 biopharmaceutical companies in China and the United States. Dr. Chen has served as the president of PROGENE BIOTECH LLC in the United States, the chief operating officer of Nanjing Simcere Pharmaceutical. He has served as the deputy general manager of biopharmaceuticals and the director of the Institute of Antibody Drugs of Shanghai Hengrui Pharmaceutical Co., Ltd, and served as the deputy general manager of Shanghai Biopharmaceutical Co., Ltd. Dr. Chen was once employed as a visiting professor at Shanghai Jiao Tong University and was awarded the honorary title of "Shanghai Pujiang Talent Award".
Dr. Chen holds a Ph.D. degree in biochemistry from the University of Georgia in the United States and a postdoctoral degree from THE SCRIPPS RESEARCH INSTITUTE in the United States. Dr. Chen has received several NIH postdoctoral scholarships and has published 14 SCI papers and owns more than 10 patents.
Managing Partner of Proxima Ventures
Managing Partner of Proxima Ventures
George Li is a Managing Partner with Proxima Ventures. George has over 15 years’ experience of founding, investing and building life science start-up companies and has accumulated hands-on experience of advising and investing early stage medtech companies, specially in interdisciplinary innovations. George led Proxima Ventures investment of Vickor, Nanoablation, Matridx, Mobidrop, Wisdom Health and serve as boarddirector of those companies.
Prior to joining Proxima Ventures,George founded Biohub which is a leading medical incubator & accelerator in China and has built a leading medical ecosystem which has offices in Wuhan, Suzhou, Zhengzhou, Chongqing and Chengdu to provide wet lab and cGMP facilities and provides access to top hospitals and KOLs in China. Biohub has incubated and supported 100+ early stage life science companies covering biotech, medical devices, diagnostic and medical services.
Prior to Biohub, George was co-founder of Biohermsand grew it into a leading IVD company in China.
George also serves as the Chair judge for Chunhui business plan contest and mentor early stage companies.
George holds a MBA from Hult International Business School and a Bachelor degree from Zhejiang University.
Managing Partner of Gobi
Managing Partner of Gobi
Partner of Tiger Jade Capital
Partner of Tiger Jade Capital
Mr. Jack Wang is currently partner of Tiger Jade Capital where he sits in investment committee and is also responsible for overall investor relationship. From June 2017 to January, 2022, Mr. Wang served as a Managing Director at CMB International Asset Management Limited (“CMBI”), where he led the firm’s effort in various notable investments including Tencent Music Entertainment Group, Xiaomi Corporation, and Grab Holdings Inc., etc and worked closely with the firm’s healthcare team and participated in project fund investing in leading healthcare companies in China, such as Burning Rock Biotech Limited and Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Prior to joining CMBI, Mr. Wang worked at CSOP Asset Management Limited from April 2012 to August 2016 with his last position being the Deputy Chief Marketing Officer, where he was instrumental in building the firm to become the largest RMB QFII player in the market. Mr. Wang also worked at Deutsche Securities Asia and Goldman Sachs (Asia) L.L.C. from November 2006 to March 2012.
Executive Director of Hillhouse Capital
Executive Director of Hillhouse Capital
Dr. Ting Xie from Hillhouse BioVenture, focuses onthe investment of cutting edge life science technologies and new therapies globally, he serves as a Board Member at various biotech companies including Elpiscience. Prior to that he worked for a Healthcare specialized Private Equity fund HCR in New York metro area and a Wall Street financial institution Alliance Bernstein covering Biotech and Spec Pharma. He obtained a Ph.D. degreefrom Harvard University, and BS degree from Tsinghua University.
Chief Commercial Officer
Chief Commercial Officer
Chief Financial Officer
Chief Financial Officer
Vice President of CMC
Vice President of CMC